
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy (NYSE:NVO)
aprott Novo Nordisk A/S (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events (‘MACE’) in early March. […]